Logo image of BLTE

BELITE BIO INC - ADR (BLTE) Stock Fundamental Analysis

NASDAQ:BLTE - Nasdaq - US07782B1044 - ADR - Currency: USD

63.19  +2.13 (+3.49%)

After market: 65.89 +2.7 (+4.27%)

Fundamental Rating

3

BLTE gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for BLTE as it has an excellent financial health rating, but there are worries on the profitability. BLTE does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year BLTE has reported negative net income.
In the past year BLTE has reported a negative cash flow from operations.
BLTE Yearly Net Income VS EBIT VS OCF VS FCFBLTE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

BLTE has a Return On Assets (-33.43%) which is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -34.99%, BLTE is in the better half of the industry, outperforming 64.06% of the companies in the same industry.
Industry RankSector Rank
ROA -33.43%
ROE -34.99%
ROIC N/A
ROA(3y)-38.23%
ROA(5y)N/A
ROE(3y)-41.11%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BLTE Yearly ROA, ROE, ROICBLTE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 -10 -20 -30 -40 -50

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BLTE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BLTE Yearly Profit, Operating, Gross MarginsBLTE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, BLTE has more shares outstanding
There is no outstanding debt for BLTE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BLTE Yearly Shares OutstandingBLTE Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 10M 20M 30M
BLTE Yearly Total Debt VS Total AssetsBLTE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

An Altman-Z score of 285.61 indicates that BLTE is not in any danger for bankruptcy at the moment.
BLTE has a better Altman-Z score (285.61) than 98.96% of its industry peers.
BLTE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 285.61
ROIC/WACCN/A
WACCN/A
BLTE Yearly LT Debt VS Equity VS FCFBLTE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 20M -20M 40M 60M 80M

2.3 Liquidity

BLTE has a Current Ratio of 24.76. This indicates that BLTE is financially healthy and has no problem in meeting its short term obligations.
BLTE has a better Current ratio (24.76) than 95.31% of its industry peers.
A Quick Ratio of 24.76 indicates that BLTE has no problem at all paying its short term obligations.
BLTE has a Quick ratio of 24.76. This is amongst the best in the industry. BLTE outperforms 95.31% of its industry peers.
Industry RankSector Rank
Current Ratio 24.76
Quick Ratio 24.76
BLTE Yearly Current Assets VS Current LiabilitesBLTE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 18.38% over the past year.
EPS 1Y (TTM)18.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, BLTE will show a very strong growth in Earnings Per Share. The EPS will grow by 40.57% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y3.53%
EPS Next 2Y-3.11%
EPS Next 3Y14.5%
EPS Next 5Y40.57%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BLTE Yearly Revenue VS EstimatesBLTE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
BLTE Yearly EPS VS EstimatesBLTE Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 4 6 8 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BLTE. In the last year negative earnings were reported.
Also next year BLTE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BLTE Price Earnings VS Forward Price EarningsBLTE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BLTE Per share dataBLTE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

A more expensive valuation may be justified as BLTE's earnings are expected to grow with 14.50% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.11%
EPS Next 3Y14.5%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BLTE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BELITE BIO INC - ADR

NASDAQ:BLTE (3/7/2025, 8:07:57 PM)

After market: 65.89 +2.7 (+4.27%)

63.19

+2.13 (+3.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)N/A N/A
Inst Owners1.1%
Inst Owner Change238.89%
Ins Owners2.2%
Ins Owner ChangeN/A
Market Cap2.01B
Analysts83.64
Price Target86.45 (36.81%)
Short Float %0.49%
Short Ratio1.74
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.03%
Min EPS beat(2)-22.36%
Max EPS beat(2)18.3%
EPS beat(4)2
Avg EPS beat(4)-12.88%
Min EPS beat(4)-61.76%
Max EPS beat(4)18.3%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)6.94%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)1.94%
EPS NY rev (3m)0.78%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 22.25
P/tB 22.25
EV/EBITDA N/A
EPS(TTM)-1.11
EYN/A
EPS(NY)-1.32
Fwd EYN/A
FCF(TTM)-0.94
FCFYN/A
OCF(TTM)-0.94
OCFYN/A
SpS0
BVpS2.84
TBVpS2.84
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -33.43%
ROE -34.99%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-38.23%
ROA(5y)N/A
ROE(3y)-41.11%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 45.32%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 24.76
Quick Ratio 24.76
Altman-Z 285.61
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)309.55%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30%
EPS Next Y3.53%
EPS Next 2Y-3.11%
EPS Next 3Y14.5%
EPS Next 5Y40.57%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-147.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-152.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-160.36%
OCF growth 3YN/A
OCF growth 5YN/A